The Zhitong Finance App learned that Sinopharm Holdings (01099) rose by nearly 3%. As of press release, it had risen 2.2% to HK$16.28, with a turnover of HK$92.691,000.

According to the news, on October 26, Sinopharm Holdings announced the results for the nine months ended September 30, 2026. The group achieved operating income of 427.613 billion yuan during the period, a year-on-year decrease of 0.9%; net profit attributable to owners of the parent company was 5.314 billion yuan, an increase of 0.13% over the previous year. Revenue for the third quarter was 144.814 billion yuan, and the year-on-year decline narrowed to 0.43%; net profit to mother for the single quarter was 1,910 billion yuan, up 3.74% year on year. In addition, in the first three quarters of Sinopharm Holdings, sales, management and financial expenses decreased by 5.93%, 3.41% and 20.95%, respectively.

According to a research report released by Citigroup, Sinopharm Holdings' revenue for the third quarter was generally in line with expectations. Net profit was slightly better than market expectations, mainly due to effective cost control. The bank believes that the company's performance is resilient, and strict cost controls offset the ongoing pressure on revenue and gross profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.